Archives
RNAPII CTD Phosphorylation: Evidence Overview
2026-10-06
A source-grounded overview of FeaSion, a study mapping RNA polymerase II CTD phosphorylation features, candidate regulators and functional effects. It compares evidence types, explains conceptual applications, and defines limitations. The supplied record does not establish MTSEA-biotin as a reagent used in the study.
EZ Cap™ Mouse CD252(OX40L) mRNA: Evidence Map
2026-10-06
This evidence-led guide explains how EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) can support causal studies of mouse OX40L-mediated immune co-stimulation. It also separates product-level interpretation from the aptamer-targeted mRNA findings reported by Paul and Al-Jamal, clarifying what the evidence does—and does not—establish.
FeaSion Maps RNA Polymerase II CTD Phosphorylation
2026-10-05
The FeaSion study builds a comparative framework for understanding five RNA polymerase II C-terminal domain phosphorylation sites by integrating interactome mapping, genomic occupancy, genetic screening, and functional replacement analyses. Its findings support a multilayered regulatory model in which site-specific phosphorylation is linked to distinct transcriptional programs, chromatin features, and regulatory enzymes, while also highlighting important limits on interpreting candidate interactions and screening hits.
YAP–TEAD Super-Enhancers in Ectoderm Commitment
2026-10-05
A 2026 Nucleic Acids Research study maps how super-enhancer networks and three-dimensional chromatin contacts coordinate early surface ectoderm commitment from pluripotent stem cells. Its perturbation and transcription-factor analyses identify YAP–TEAD activity, particularly TEAD-dependent regulation, as an upstream mechanism that promotes enhancer establishment and lineage-associated gene activation.
Biomimetic mRNA Nanovaccines Target Tumor Neutrophils
2026-10-04
A 2026 Acta Pharmaceutica Sinica B study reports a biomimetic mRNA nanovaccine designed to recognize CD300LD-enriched tumor-associated neutrophils and deliver an IL-36γ-based immune-activating payload. In mouse hepatocellular carcinoma models, the platform promoted antitumor immune activity and was associated with an 85% survival rate in the reported treatment group, although translation beyond the study models remains uncertain.
Dimetridazole Hydroxyl-Radical Degradation: Key Findings
2026-10-03
A quantum-chemical study mapped how hydroxyl radicals transform Dimetridazole and ornidazole in aqueous environments, combining reaction mechanisms, modeled kinetics, and toxicity predictions. The findings suggest rapid radical-initiated transformation but also show that early products may temporarily increase aquatic toxicity, so chemical removal should not be equated with complete risk elimination.
Sulfo-NHS-Biotin for Protein Labeling
2026-10-02
Sulfo-NHS-Biotin is a water-soluble, amine-reactive protein labeling reagent for covalent biotinylation of accessible primary amines. Its membrane-impermeant behavior supports cell surface protein labeling, while its aqueous compatibility supports affinity chromatography and immunoprecipitation workflows.
Novel PDK4 Inhibitors for Metabolic Disease
2026-10-01
The 2019 Journal of Medicinal Chemistry study developed anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4 (PDK4), identifying compound 8c as a nanomolar biochemical inhibitor with activity in metabolic, allergic, and cancer-related models. Its integrated use of structure–activity optimization, metabolic stability, pharmacokinetic studies, animal efficacy testing, and molecular docking provides a useful framework for evaluating PDK4-directed drug candidates while also exposing the limits of early preclinical translation.
Amikacin Sulfate: Assay Design and Delivery
2026-10-01
Build a defensible Amikacin workflow by separating planktonic potency, intracellular exposure, toxicity, and granuloma-level distribution. The result is a practical framework for comparing free drug with targeted delivery systems while avoiding unsupported translational conclusions.
GS-441524 Workflows for Antiviral Research
2026-09-30
Build more reliable GS-441524 antiviral assays by separating parent-compound exposure, intracellular activation, and prodrug conversion. This workflow combines practical solubility and storage guidance with LC–MS/MS strategies for cell, gastric, blood, liver-microsome, and pharmacokinetic studies.
Shrimp STING DNA Sensing and IFN-Like Antiviral Defense
2026-09-30
A 2024 study shows that Litopenaeus vannamei STING can directly recognize double-stranded DNA as well as cyclic dinucleotides, extending the established STING model beyond mammalian systems. The work defines a DNA–STING–IKKε–IRF–Vago4 pathway that produces an IFN-like antiviral state and offers a comparative framework for studying the evolution of cytosolic nucleic-acid sensing.
HABA Assays for PLGA Microsphere Design
2026-09-29
HABA converts avidin–biotin recognition into a practical absorbance readout for evaluating functional ligand accessibility on PLGA microspheres. Used alongside particle sizing, zeta potential, release testing, and HPLC, it helps distinguish surface chemistry that is merely present from chemistry that remains biologically accessible.
Merimepodib: Targeting IMPDH for Translation
2026-09-29
Merimepodib (VX-497) offers a research-ready way to interrogate IMPDH-dependent guanine nucleotide biosynthesis across antiviral, immunology, and oncology workflows. Recent PEDV findings strengthen the mechanistic case for host-directed antiviral research while highlighting the need for cell-specific controls, guanosine rescue, and careful separation of antiproliferative effects from antiviral activity.
HotStart qPCR Master Mix for hly Gene Analysis
2026-09-28
HotStart Universal 2X FAST Green qPCR Master Mix supports rapid, dye-based gene expression analysis with hot-start Taq chemistry and a fixed ROX reference dye. For Listeria monocytogenes hly studies, it can support transcript quantification, but melt curve analysis and appropriate controls remain necessary for specificity.
EGFP mRNA m1Ψ: Practical Reporter Workflows
2026-09-28
Use EGFP mRNA m1Ψ to separate delivery, translation, cell health, and fluorescence timing—not just to score a single transfection endpoint. This practical workflow pairs dose and time-course controls with a recent mRNA-stability study, while keeping its engineered stabilizing elements distinct from the reporter product.